Tandem Investment Advisors Inc. Invests $32.19 Million in Zoetis Inc. (NYSE:ZTS)

Tandem Investment Advisors Inc. acquired a new stake in shares of Zoetis Inc. (NYSE:ZTS) in the fourth quarter, Holdings Channel reports. The firm acquired 197,537 shares of the company’s stock, valued at approximately $32,185,000.

Several other large investors also recently added to or reduced their stakes in the stock. Darwin Wealth Management LLC bought a new stake in shares of Zoetis during the third quarter valued at approximately $31,000. First Personal Financial Services purchased a new position in Zoetis during the 3rd quarter worth $33,000. Capital Performance Advisors LLP purchased a new position in Zoetis during the 3rd quarter worth $33,000. Dunhill Financial LLC raised its position in Zoetis by 80.6% during the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares in the last quarter. Finally, Atlantic Edge Private Wealth Management LLC lifted its holdings in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after buying an additional 140 shares during the period. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Price Performance

Shares of ZTS opened at $157.38 on Friday. The company has a 50 day moving average of $166.86 and a two-hundred day moving average of $178.14. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The company has a market cap of $70.47 billion, a price-to-earnings ratio of 28.77, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. As a group, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.27%. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Analysts Set New Price Targets

Several equities analysts have recently commented on ZTS shares. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Stifel Nicolaus cut their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Leerink Partners assumed coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target for the company. Piper Sandler dropped their price objective on shares of Zoetis from $210.00 to $200.00 and set an “overweight” rating on the stock in a research note on Monday, February 10th. Finally, Barclays boosted their price objective on shares of Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research note on Friday, February 14th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Zoetis currently has a consensus rating of “Buy” and an average target price of $214.90.

Insider Activity at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is currently owned by insiders.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.